Photocure Embraces Change with the Appointment of Jane Healy as New VP and GM for EMEA

Photocure Welcomes Jane Healy as New Vice President and General Manager for EMEA

In a strategic move that signals a commitment to growth and innovation, Photocure ASA, a company renowned for its focus on bladder cancer solutions, has officially appointed Jane Healy as the Vice President and General Manager for the EMEA region. This announcement was made on March 26, 2025, and highlights the company's ambition to bolster its presence in uro-oncology at a crucial juncture in the healthcare landscape.

Jane Healy arrives at Photocure with a wealth of experience gathered over a remarkable 30-year career in the medical device industry. She has held pivotal roles in renowned organizations, including St Jude Medical, CR Bard, and Boston Scientific, where she served as Vice President for EMS in the Peripheral Interventions Division. Her extensive experience encompasses sales, marketing, and management within the medical device sector.

"We are very pleased to welcome Jane to the Photocure team during such an important phase for our company," stated Dan Schneider, President and CEO. "Her diverse background and established expertise in healthcare and medical devices will be vital for us as we pursue our growth objectives in uro-oncology."

Healy holds a BA (Hons) in Modern Languages from the prestigious Cambridge University and speaks multiple languages, including English, French, German, and Italian. This multicultural proficiency is likely to enhance her interactions across various regions within the EMEA territory, facilitating Photocure’s efforts to connect with diverse healthcare professionals and stakeholders.

Since the re-establishment of its European operations in 2020, Photocure has been focused on leading innovations in bladder cancer care. The recent appointment of Healy is expected to accelerate this momentum, especially following the company's acquisition of Hexvix® sales and distribution rights. Hexvix® has been instrumental in improving bladder cancer diagnostics, allowing for enhanced visualization of malignant cells, thereby leading to better treatment outcomes. Schneider further emphasized that Healy's ability to create and nurture international teams would be crucial in positioning Photocure as a leader in enabling effective bladder cancer patient care.

Bladder cancer is a significant global health concern, ranking as the 8th most common cancer worldwide, with a notably high incidence in men. The disease presents challenges due to its high recurrence rate and the complexities involved in treatment. As the industry adapts to these challenges, leadership that embodies both expertise and vision becomes essential. Healy’s appointment comes at a time when the uro-oncology field is marked by substantial advancements and attention.

"With Jane at the helm of our EMEA operations, I am optimistic about the future trajectory of Photocure as we continue our mission to improve the lives of bladder cancer patients. Her leadership will undoubtedly guide us toward achieving our goals and fostering a culture of innovative healthcare solutions, benefiting both patients and healthcare providers alike," concluded Schneider.

Photocure is committed to turning the tide against bladder cancer and enhancing the precision in diagnostics. The company’s innovative use of Blue Light Cystoscopy (BLC) technology with Hexvix® has proven to improve tumor detection significantly, allowing for better surgical outcomes and more informed treatment pathways.

As Jane Healy steps into her new role, the medical community and stakeholders will closely watch the unfolding results of her leadership at Photocure. The company is determined to solidify its position within the dynamic landscape of healthcare, exemplifying what is possible when expertise and dedication align for a greater cause.